Bitte aktivieren Sie Javascript um alle Funktionen nutzen zu können und ihre Nutzererfahrung zu verbessern.
EHC 2022
Programm
Poster
Personen
Suche
EN
Alle Personen
Robert Croop
Sortiert nach Typ
Datum
Vortrag
09.12.2022
15:40
–
15:45
3 Min.
2 Min.
ePoster
P104
A Phase 2/3 Open-label, Long-term, Safety Trial of Zavegepant 10 mg Nasal Spray for the Acute Treatment of Migraine
CGRP inhibitors in the clinic, Migraine
09.12.2022
16:40
–
16:45
3 Min.
2 Min.
ePoster
P149
Safety and Tolerability of Rimegepant Every Other Day for Preventive Treatment of Migraine Plus As-Needed for Acute Treatment of Migraine: Results from A 52-Week, Open-Label Extension Study
CGRP inhibitors in the clinic, Migraine
09.12.2022
16:50
–
16:55
3 Min.
2 Min.
ePoster
P136a
Efficacy and Safety of Zavegepant Nasal Spray for the Acute Treatment of Migraine: Results of a Phase 3 Double-Blind, Randomized, Placebo Controlled Trial
CGRP inhibitors in the clinic, Migraine
Weitere Beteiligungen
09.12.2022
15:30
–
15:35
3 Min.
2 Min.
ePoster
P115
Rimegepant for the Acute Treatment of Migraine: Subgroup Analyses From 3 Phase 3 Clinical Trials by Triptan Treatment Experience
CGRP inhibitors in the clinic, Migraine
09.12.2022
15:40
–
15:45
3 Min.
2 Min.
ePoster
P104
A Phase 2/3 Open-label, Long-term, Safety Trial of Zavegepant 10 mg Nasal Spray for the Acute Treatment of Migraine
CGRP inhibitors in the clinic, Migraine
09.12.2022
15:40
–
15:45
3 Min.
2 Min.
ePoster
P122
Oral Rimegepant 75 mg is Safe and Well Tolerated in Adults With Migraine and Cardiovascular Risk Factors: Results of a Multicenter, Long-Term, Open-Label Safety Study
CGRP inhibitors in the clinic, Migraine
09.12.2022
15:45
–
15:50
3 Min.
2 Min.
ePoster
P123
Medication Preference, Satisfaction, and Clinical Improvement Among Adults Receiving Long-Term Treatment With Rimegepant for Migraine
CGRP inhibitors in the clinic, Migraine
09.12.2022
16:40
–
16:45
3 Min.
2 Min.
ePoster
P149
Safety and Tolerability of Rimegepant Every Other Day for Preventive Treatment of Migraine Plus As-Needed for Acute Treatment of Migraine: Results from A 52-Week, Open-Label Extension Study
CGRP inhibitors in the clinic, Migraine
09.12.2022
16:45
–
16:50
3 Min.
2 Min.
ePoster
P148
Effects of Rimegepant 75 mg on Monthly Migraine Days: a 52-Week, Open-Label Extension Study
CGRP inhibitors in the clinic, Migraine
09.12.2022
16:50
–
16:55
3 Min.
2 Min.
ePoster
P136a
Efficacy and Safety of Zavegepant Nasal Spray for the Acute Treatment of Migraine: Results of a Phase 3 Double-Blind, Randomized, Placebo Controlled Trial
CGRP inhibitors in the clinic, Migraine
© Conventus Congressmanagement & Marketing GmbH
Impressum
Datenschutz